Defunct Company
Total Trials
10
As Lead Sponsor
As Collaborator
0
Total Enrollment
1,116
NCT00386165
Safety Study of Larazotide Acetate to Treat Celiac Disease.
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 29, 2005
Completion: Jan 26, 2006
NCT00386490
Safety of Larazotide Acetate in Healthy Volunteers
Start: Jan 10, 2006
Completion: Feb 27, 2006
NCT00362856
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
Phase: Phase 2
Start: Sep 13, 2006
Completion: Mar 6, 2007
NCT00492960
Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease
Start: Aug 31, 2007
Completion: Mar 31, 2009
NCT00620451
Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease
Start: Feb 29, 2008
Completion: Dec 31, 2009
NCT00889473
Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease
Start: Apr 30, 2009
Completion: Apr 30, 2010
NCT01396213
A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease
Start: Nov 7, 2011
Completion: Aug 20, 2013
NCT03569007
Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms
Phase: Phase 3
Start: May 29, 2019
Completion: Jul 21, 2022
NCT04379856
Proof of Concept Study in Patients With Short Bowel Syndrome
Phase: Phase 1/2
Start: Jun 23, 2020
Completion: Dec 31, 2020
NCT04988997
VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome.
Start: Jun 14, 2021
Completion: Aug 24, 2022